News | June 03, 2008

New ECG Monitor Extends its Leads to Three

June 4, 2008 - Card Guard AG has received 510(k) clearance from the FDA for its next-generation LifeStar ACT III Platinum system with 3-lead ECG functionality, designed to enable the tracking of vital heart rhythm information in real-time.

The device’s DSI product code defines real-time arrhythmia detection and alarm, including ST-segment measurement and alarm to meet the U.S. Payor and Medicare reimbursement requirements.

The LifeStar ACT III Platinum system, based on the existing LifeStar ACT I (1-lead ECG) system, features a reportedly enhanced heart arrhythmia detection capabilities thanks to its 3-lead ECG functionality. Like the successful LifeStar ACT I system, the new 3-lead version offers the same full auto-detect and auto-send device functionality and therefore does not require any patient interaction.

The LifeStar ACT system is said to automatically detect and send heart rhythm abnormalities to a LifeWatch monitoring call center that is staffed 24 hours/7 days a week/365 days a year by specialized cardiac technicians who can immediately interpret the data and initiate any necessary next steps. LifeStar ACT devices can enhance the diagnostic yields, and be of life-saving value.

The LifeStar ACT III Platinum’s ability to place 3 ECG leads comfortably on a patient’s chest enhances the ability to obtain vital heart rhythm information, which typically requires the use of 12-lead ECGs in a stationary setting.

According to the company, the ACT III Platinum platform has the potential to expand the market by extending to the outpatient setting real-time ambulatory cardiac telemetry. This will enable monitoring of additional patient conditions, such as myocardial ischemia, the cause of angina pectoris.

For more information: www.lifewatch.com

Related Content

OTC ECG devices

OTC ECG devices can help detect abnormal heart rhythms in the general population, and this technology will continue to improve.

Feature | ECG | March 11, 2020
Apple created a stir when it...
Several wearable, less-obtrusive ECG monitors fhave been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 

Several wearable, less-obtrusive ECG monitors have been cleared by the FDA for longer wear. This example is Cardiac Insight’s Cardea SOLO device. 

Feature | ECG | February 19, 2020
When the patients of Michael Boler, M.D. need cardiac monitoring, the Holter monitor is no longer his first choice. “...
The Bittium Faros uses a 4-in-1 ECG technology. It is a lightweight, waterproof and can be configured for different patient monitoring needs. Bittium Faros Holter monitoring.

The Bittium Faros uses a 4-in-1 ECG technology. It is a lightweight, waterproof and can be configured for different patient monitoring needs. 
 

News | ECG | January 22, 2020
January 22, 2020 – Bittium is exhibiting solutions for cardiology at...
Cardiologs
News | ECG | December 12, 2019
December 12, 2019 — Cardiologs, a global leader in artificial intelligence (AI)
FDA Clears AliveCor's KardiaMobile 6L as First Six-Lead Personal ECG Device
Technology | ECG | May 13, 2019
AliveCor announced its third U.S. Food and Drug Administration (FDA) clearance in three months, making KardiaMobile 6L...
One innovation in ECG is its use in the customer wearable market, which will tie more closely into the clinical world either with using the data to triage patients and/or patients seeking medical attention prior to acute symptoms appearing.

One innovation in ECG is its use in the customer wearable market, which will tie more closely into the clinical world either with using the data to triage patients and/or patients seeking medical attention prior to acute symptoms appearing.

Feature | ECG | May 03, 2019 | Sanket Solanki
Technology has made its way into the healthcare sector and brought a drastic transformation.
Videos | ECG | March 05, 2019
This is a quick demo of the Schiller Cardiovit FT-1 electrocardiograph (ECG) system displayed at the ...
EKG With Artificial Intelligence Reliably Detects Heart Failure Precursor
News | ECG | January 08, 2019
January 8, 2019 — A Mayo Clinic study finds that applying...
Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use an adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer.

Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use a small, adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer. 

Feature | ECG | September 27, 2018
Advances in the technology of wearable cardiac monitors are improving both the experience of the patient and the effe
HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function
News | ECG | April 27, 2018
HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous...